Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
M&A / Property

Optimi psilocybin capsules included in Medibank program

By The Northwire Desk — AI Analysis Oct 06, 2025 · 17:02 OPTI · 0.375 Optimi Health Corp
OPTI · Price

Executive Summary

  • Optimi Health’s 5 mg naturally derived psilocybin capsules have been selected for inclusion in Medibank’s $10 M insurance‑backed psychotherapy program for treatment‑resistant depression (TRD).
  • The program is part of Medibank’s broader $50 M, five‑year initiative to expand access to novel mental‑health therapies, including psilocybin and MDMA.
  • Delivery of clinical services will be performed by Emyria Ltd.’s Empax Centre in Perth, with Optimi’s exclusive Australian distributor Mind Medicine Australia facilitating capsule supply.

Key Details

  • Program Funding: $10 M (Australian) allocated by Medibank to reimburse psilocybin‑assisted therapy for TRD patients.
  • Broader Initiative: Medibank has committed $50 M (Australian) over five years to mental‑health innovation, prevention, and access.
  • Distribution Chain: Emyria Ltd., via its wholly owned Empax Centre (Perth, WA), will deliver clinical services; Mind Medicine Australia is the exclusive distributor for Optimi’s capsules in Australia.
  • Product Availability: Optimi’s psilocybin capsules have been available in Australia since 3 Sept 2025 under the authorized prescriber scheme.
  • Company Footprint: Optimi operates two GMP‑compliant facilities (10,000 sq ft each) in British Columbia, licensed by Health Canada for controlled substances. Products are marketed in Australia (prescription) and Canada (special access program).

Notable Quotes

“The inclusion of our psilocybin capsules in Medibank's insurance‑backed program for treatment‑resistant depression reflects the growing role of standardized psychedelic medicines in insured mental health care… marks an important step towards Optimi's integration into insurance‑backed regulated care.” – Dane Stevens, CEO, Optimi Health Corp.

Read the original news release →

More from Optimi Health Corp

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory